Peter Vuylsteke

7.3k total citations · 1 hit paper
101 papers, 1.7k citations indexed

About

Peter Vuylsteke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Peter Vuylsteke has authored 101 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Peter Vuylsteke's work include Ovarian cancer diagnosis and treatment (18 papers), HER2/EGFR in Cancer Research (17 papers) and Breast Cancer Treatment Studies (15 papers). Peter Vuylsteke is often cited by papers focused on Ovarian cancer diagnosis and treatment (18 papers), HER2/EGFR in Cancer Research (17 papers) and Breast Cancer Treatment Studies (15 papers). Peter Vuylsteke collaborates with scholars based in Belgium, United States and Netherlands. Peter Vuylsteke's co-authors include Gabe S. Sonke, Christopher Poole, Michael Friedländer, Helen Mackay, Nicoletta Colombo, David Cibula, Amit M. Oza, Ron H.J. Mathijssen, Jiří Špaček and Jacqui Rowbottom and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Vuylsteke

91 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Gabe S. Sonke, Nicoletta Colombo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Vuylsteke Belgium	19	1.1k	439	411	383	366	101	1.7k
Marta Gil-Martín Spain	20	1.2k 1.1×	629 1.4×	526 1.3×	322 0.8×	232 0.6×	108	2.0k
Véronique D’Hondt France	21	781 0.7×	298 0.7×	335 0.8×	241 0.6×	276 0.8×	83	1.3k
Anthony Kong United Kingdom	27	825 0.7×	561 1.3×	361 0.9×	193 0.5×	280 0.8×	73	1.8k
Jane Robertson United Kingdom	22	1.3k 1.1×	816 1.9×	510 1.2×	283 0.7×	340 0.9×	57	2.0k
Anton Scharl Germany	20	644 0.6×	248 0.6×	277 0.7×	438 1.1×	160 0.4×	127	1.5k
Salvatore Lopez Italy	25	551 0.5×	369 0.8×	213 0.5×	183 0.5×	619 1.7×	89	1.6k
Kathryn P. Gray United States	22	959 0.8×	622 1.4×	1.0k 2.5×	657 1.7×	129 0.4×	75	2.0k
Eirini Pectasides Greece	24	621 0.5×	617 1.4×	388 0.9×	289 0.8×	600 1.6×	49	1.8k
Dominique Berton-Rigaud France	18	1.0k 0.9×	217 0.5×	238 0.6×	277 0.7×	655 1.8×	73	1.8k
Jean‐Pascal Machiels Belgium	23	808 0.7×	461 1.1×	290 0.7×	256 0.7×	84 0.2×	58	1.6k

Countries citing papers authored by Peter Vuylsteke

Since Specialization

Citations

This map shows the geographic impact of Peter Vuylsteke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Vuylsteke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Vuylsteke more than expected).

Fields of papers citing papers by Peter Vuylsteke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Vuylsteke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Vuylsteke. The network helps show where Peter Vuylsteke may publish in the future.

Co-authorship network of co-authors of Peter Vuylsteke

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Vuylsteke. A scholar is included among the top collaborators of Peter Vuylsteke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Vuylsteke. Peter Vuylsteke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

MacDuffie, Emily, Barati Monare, Peter Vuylsteke, et al.. (2025). Assessing the impact of multidisciplinary team gynecological oncology care in Botswana: A potential model for low‐ and middle‐income countries. Cancer. 131(16). e70006–e70006.

Vuylsteke, Peter, et al.. (2023). Breast cancer patient experiences in the Botswana health system: Is it time for patient navigators?. Journal of Cancer Policy. 38. 100449–100449.

Davies, Lynne, Danny A. Milner, Lawrence N. Shulman, et al.. (2023). Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities. JCO Global Oncology. 9(9). e2200203–e2200203. 3 indexed citations

Wildiers, Hans, Anne Armstrong, Eveline Cuypere, et al.. (2023). Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clinical Cancer Research. 30(3). 532–541. 12 indexed citations

Brandão, Mariana, Diogo Martins-Branco, Claudia De Angelis, et al.. (2023). Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium. Breast Cancer Research and Treatment. 203(2). 351–363. 4 indexed citations

Aronson, S. Lot, Marta López‐Yurda, Simone N. Koole, et al.. (2023). Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. The Lancet Oncology. 24(10). 1109–1118. 55 indexed citations

Agostinetto, Elisa, Mariana Brandão, Denis Larsimont, et al.. (2023). Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 522–522. 1 indexed citations

Jaeghere, Emiel A. De, Sandra Tuyaerts, Ann Belmans, et al.. (2022). 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial. International Journal of Gynecological Cancer. 32. A187–A188.

Lago, Lissandra Dal, Corneel Coens, Peter Vuylsteke, et al.. (2022). Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. Journal of Geriatric Oncology. 13(5). 582–593. 8 indexed citations

10.

Wu, Qi, Barbara Brouwers, Bruna Dalmasso, et al.. (2022). Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study. Translational Oncology. 25. 101527–101527. 5 indexed citations

11.

Gombos, Andrea, David Venet, Lieveke Ameye, et al.. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. npj Breast Cancer. 7(1). 125–125. 14 indexed citations

12.

Colombo, Nicoletta, Justine Gantzer, Beyhan Ataseven, et al.. (2020). 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Annals of Oncology. 31. S614–S614. 2 indexed citations

13.

Wildiers, Hans, Konstantinos Tryfonidis, Lissandra Dal Lago, et al.. (2018). Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology. 19(3). 323–336. 81 indexed citations

14.

Trillsch, Fabian, Sven� Mahner, Felix Hilpert, et al.. (2016). Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Annals of Oncology. 27(9). 1733–1739. 20 indexed citations

15.

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PLoS ONE. 11(3). e0147599–e0147599. 16 indexed citations

16.

Bonnefoi, Hervé, William Jacot, Mahasti Saghatchian, et al.. (2014). Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Annals of Oncology. 26(2). 325–332. 56 indexed citations

17.

Pattyn, Piet, et al.. (2013). Desmoid Tumour of the Breast: Case Report and Review of the Literature. Acta chirurgica Belgica. 113(4). 304–307. 2 indexed citations

18.

Azim, Hatem A., Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2013). Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. Journal of Clinical Oncology. 31(36). 4504–4511. 45 indexed citations

19.

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2011). First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586). Journal of Clinical Oncology. 1 indexed citations

20.

Wildiers, Hans, Christel Fontaine, Peter Vuylsteke, et al.. (2010). Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123(2). 463–469. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact